Abstract:As one of the most common breast cancer subtypes, luminal A breast cancer is sensitive to endocrine-based therapy and insensitive to chemotherapy. Patients with luminal A subtype of breast cancer have a relatively good prognosis compared with that of patients with other subtypes of breast cancer. However, with the increased incidence in endocrine resistance and severe side effects, simple endocrine therapy has become unsuitable for the treatment of luminal A breast cancer. Therefore, identifying novel therapeutic targets for luminal A breast cancer may accelerate the development of an effective therapeutic strategy. The bioinformatical analysis of the current study, which included KEGG and GO analyses of the GSE20437 dataset containing 24 healthy and 18 breast cancer tissue samples, identified key target genes associated with breast cancer. Moreover, survival analysis results revealed that a low expression of BTG2 was significantly associated with the low survival rate of patients with breast cancer, indicated that B-cell translocation gene 2 (BTG2) may be a potential target in breast cancer. However, BTG2 may be cancer type-dependent, as overexpression of BTG2 has been demonstrated to suppress the proliferation of pancreatic and lung cancer cells, but promote the proliferation of bladder cancer cells. Since the association between BTG2 and luminal A-subtype breast cancer remains unclear, it is important to understand the biological function of BTG2 in luminal A breast cancer. Based on the expression levels of estrogen receptor, progesterone receptor and human epidermal growth factor receptor, MCF-7 cells were selected in the present study as a luminal A breast cancer cell type. MTT, Transwell invasion and wound healing assays revealed that overexpression of BTG2 suppressed the levels of MCF-7 cell proliferation, migration and invasion. In addition, the downregulation of BTG2 at the mRNA and protein level was also confirmed in luminal A breast tumor tissue, which was consistent with the results in vitro. These results indicated that BTG2 may act as an effective target for the treatment of luminal A breast cancer.

Btg1 Inhibits Breast Cancer Cell Growth Through Induction Of Cell Cycle Arrest And Apoptosis

B‑cell translocation 1 gene inhibits cellular metastasis‑associated behavior in breast cancer.

Upregulation of BTG1 Enhances the Radiation Sensitivity of Human Breast Cancer in Vitro and in Vivo

BTG2 Inhibits the Proliferation, Invasion, and Apoptosis of MDA-MB-231 Triple-Negative Breast Cancer Cells

BTG1 potentiates apoptosis and suppresses proliferation in renal cell carcinoma by interacting with PRMT1.

Btg1 Expression Correlates With The Pathogenesis And Progression Of Ovarian Carcinomas

The roles of BTG1 mRNA expression in cancers: A bioinformatics analysis

BTG1 Overexpression Might Promote Invasion and Metastasis of Colorectal Cancer via Decreasing Adhesion and Inducing Epithelial–Mesenchymal Transition

The effect of BTG1 expression on proliferation, apoptosis and invasion of non-small cell lung cancer cells

BTG2 overexpression increases the radiosensitivity of breast cancer cells in vitro and in vivo.

The expression of BTG1 is downregulated in NSCLC and possibly associated with tumor metastasis

Expression of BTG1 in HK-2 and 786-O and Its Influence on Cell Cycle and Apoptosis of HK-2 and 786-O

BTG2 As a Tumor Target for the Treatment of Luminal A Breast Cancer

Bone Marrow Stromal Cell-derived Growth Inhibitor Inhibits Growth and Migration of Breast Cancer Cells Via Induction of Cell Cycle Arrest and Apoptosis*

Effects of BTG2 Overexpression on the Radiosensitivity of Human Breast Cancer T-47D Cells

RETRACTED ARTICLE: Pttg1 Inhibits TGFβ Signaling in Breast Cancer Cells to Promote Their Growth

TIEG1 Inhibits Breast Cancer Invasion and Metastasis by Inhibition of Epidermal Growth Factor Receptor (EGFR) Transcription and the EGFR Signaling Pathway

Effect of CDK7 Inhibitor THZ1 on Proliferation and Apoptosis of Breast Cancer Cells and Related Mechanism

Suppression of PTTG1 Inhibits Cell Angiogenesis, Migration and Invasion in Glioma Cells

TuBG1 promotes hepatocellular carcinoma via ATR/P53-apoptosis and cycling pathways

BTG2 Suppresses the Growth and Metastasis of Cervical Squamous Cell Carcinoma